Systematic reviews on selected pharmacogenetic tests for cancer treatment: CYP2D6 for tamoxifen in breast cancer, KRAS for anti-EGFR antibodies in colorectal cancer, and BCR-ABL1 for tyrosine kinase inhibitors in chronic myeloid leukemia

Terasawa T, Dahabreh I, Castaldi PJ, Trikalinos TA

Record Status
This is a systematic review that meets the criteria for inclusion on DARE.

Bibliographic details
Terasawa T, Dahabreh I, Castaldi PJ, Trikalinos TA. Systematic reviews on selected pharmacogenetic tests for cancer treatment: CYP2D6 for tamoxifen in breast cancer, KRAS for anti-EGFR antibodies in colorectal cancer, and BCR-ABL1 for tyrosine kinase inhibitors in chronic myeloid leukemia. Rockville, MD, USA: Agency for Healthcare Research and Quality. Technology Assessment. 2010

Original Paper URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Cytochrome P-450 CYP2D6; Genetic Testing; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmacogenetics; Protein Kinase Inhibitors; Proto-Oncogene Proteins; ras Proteins; Receptor, Epidermal Growth Factor; Tamoxifen

AccessionNumber
12011000900

Date bibliographic record published
13/04/2011